Patient P-03225
Therapy response
Stable
Tolerance
Deteriorating
GI state
Deteriorating
Inflammatory state
Stable
Nutritional resilience
Stable
Discontinuation risk
56%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S19
- Day 102 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 102 GI-04 recommended — GI Support Protocol GI-04
- Day 103 Patient accepted — Started GI-04 in the companion
- Day 111 GI symptom burden −29% vs expected — GI Support Protocol GI-04
- Day 117 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 102.
Primary contributors, last 14 days
- Treatment adherence-12
- Toxicity+9
- GI instability+5
- Inflammatory activity+3
What helped?
- GI Support Protocol GI-04Day 102Result: symptom burden −29%
LIFE OS recommendation
Dosing / Timing Recommendation DT-01
66%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 80% showed improvement
- median effect visible after 5 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 55 and rising
- WearableSleep 5.2 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 38/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 45
- Autonomic recovery ↓45
- WearableResting HR 80 bpm
- WearableShort sleep window
- Inflammatory signalling ↑25
- BloodInflammatory load index 54
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 2.6 · butyrate capacity 38/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 41 ms
- Sleep
- 5.5 h
- Steps
- 8,533
- Resting HR
- 79 bpm
Daily log: GI score 55, nutritional resilience 43, adherence 70.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.